Han-Chih Chang

Title: Han-Chih Chang: Innovator in Nuclear Medicine Imaging

Introduction

Han-Chih Chang is a prominent inventor based in Taoyuan, Taiwan. He has made significant contributions to the field of nuclear medicine, particularly in the development of imaging compounds for tracking neurodegenerative diseases and tumors. With a total of 3 patents, his work is pivotal in advancing medical imaging technologies.

Latest Patents

Chang's latest patents include a precursor of a histone deacetylase inhibitor PET imaging compound. This compound is designed for tracking cerebral neurodegenerative and tumor diseases. The method provided involves labeling a nuclear medicine for imaging tracing, which comprises a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and its derivatives. The first class of derivatives includes BNL-26 and its variants, while the second class focuses on indole/indoline derivatives that serve as labeling precursors for histone acetylation inhibitors. These innovations are crucial for the diagnosis and treatment of malignant tumors through advanced imaging techniques.

Career Highlights

Throughout his career, Han-Chih Chang has worked with esteemed organizations such as the Institute of Nuclear Energy Research and the Atomic Energy Council, Executive Yuan. His expertise in nuclear medicine has positioned him as a key figure in the development of imaging technologies that enhance diagnostic capabilities.

Collaborations

Chang has collaborated with notable colleagues, including Ming-Hsin Li and Chyng-Yann Shiue. These partnerships have fostered innovation and contributed to the advancement of nuclear medicine research.

Conclusion

Han-Chih Chang's contributions to nuclear medicine imaging are invaluable. His innovative patents and collaborations highlight his commitment to improving diagnostic methods for neurodegenerative diseases and tumors. His work continues to influence the field and pave the way for future advancements in medical imaging technologies.